Pacific Point Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.31M Buy
1,420
+7
+0.5% +$7.1K 0.69% 51
2025
Q4
$1.52M Buy
1,413
+174
+14% +$166K 0.81% 32
2025
Q3
$945K Buy
1,239
+4
+0.3% +$2.98K 0.55% 60
2025
Q2
$963K Hold
1,235
0.52% 53
2025
Q1
$1.02M Hold
1,235
0.57% 45
2024
Q4
$1.02M Buy
+1,235
New +$1.02M 0.62% 47

Other funds holding LLY

Pacific Point Advisors's LLY Position: Q1 2026 in Review

Pacific Point Advisors increased its Eli Lilly (LLY) stake by 0.5% in Q1 2026, buying an estimated $7.1K and bringing the position to 1,420 shares worth $1.31M. The position accounts for 0.69% of the portfolio, ranked #51.

Pacific Point Advisors first reported a position in LLY in Q4 2024 and has held it in 6 quarters since. The position peaked at $1.52M in Q4 2025. 4,352 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Pacific Point Advisors held 1,420 shares of Eli Lilly worth $1.31M as of Q1 2026.
  • Pacific Point Advisors bought 7 Eli Lilly shares in Q1 2026, an estimated $7.1K.
  • Eli Lilly made up 0.69% of Pacific Point Advisors's portfolio in Q1 2026, its #51 holding.
  • Pacific Point Advisors first reported a position in Eli Lilly in Q4 2024 and has held it in 6 quarters since.
  • Pacific Point Advisors's Eli Lilly position peaked at $1.52M in Q4 2025.
  • 4,352 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Pacific Point Advisors's 13F filing for Q1 2026, filed 4 May 2026.